| Status | 已發表Published |
| Nanomedicine-combined immunotherapy for cancer | |
Huang, S. ; Zhao, Q.
| |
| 2020-10-01 | |
| Source Publication | Current Medicinal Chemistry
 |
| ISSN | 0929-8673 |
| Pages | 5716-5729 |
| Abstract | mmunotherapy for cancer includes chimeric antigen receptor (CAR)-T cells, CAR-natural killer (NK) cells, PD1, and the PD-L1 inhibitor. However, the proportion of patients who respond to cancer immunotherapy is not satisfactory. Concurrently, nanotechnology has experienced a revolution in cancer diagnosis and therapy. There are few clinically approved nanoparticles that can selectively bind and target cancer cells and incorporate molecules, although many therapeutic nanocarriers have been approved for clinical use. There are no systematic reviews outlining how nanomedicine and immunotherapy are used in combination to treat cancer. |
| Keyword | CAR-NK cells Cancer immunotherapy drug delivery nanomedicine synergistic effect |
| URL | View the original |
| Language | 英語English |
| The Source to Article | PB_Publication |
| PUB ID | 45914 |
| Document Type | Journal article |
| Collection | DEPARTMENT OF BIOMEDICAL SCIENCES |
| Corresponding Author | Zhao, Q. |
| Recommended Citation GB/T 7714 | Huang, S.,Zhao, Q.. Nanomedicine-combined immunotherapy for cancer[J]. Current Medicinal Chemistry, 2020, 5716-5729. |
| APA | Huang, S.., & Zhao, Q. (2020). Nanomedicine-combined immunotherapy for cancer. Current Medicinal Chemistry, 5716-5729. |
| MLA | Huang, S.,et al."Nanomedicine-combined immunotherapy for cancer".Current Medicinal Chemistry (2020):5716-5729. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment